April 13th 2022
Results of the phase 2 AURELIO-03 trial show SOT101 plus PD-1 inhibition induced responses in patients with advanced solid tumors.
Trial-Ineligible Patients With Advanced Solid Tumors More Likely to Receive Immune Checkpoint Inhibitor MonotherapyNovember 17th 2021
Patients with advanced cancers who were ineligible for trials were more likely to receive frontline immune checkpoint inhibitor monotherapy than patients with the same advanced cancers who were eligible for trials.
PD-1 and PD-L1 Inhibitors Yield a Higher Risk of AEs in Combination With Chemotherapy vs Targeted Therapy or ImmunotherapySeptember 21st 2021
The toxicity profiles of PD-1 and PD-L1 inhibitors displayed unique characteristics when combines with other agents such as chemotherapy, targeted therapy, and immunotherapy.
VERSATILE-002 Trial to Enroll Previously Treated HPV+ HNSCC Per Protocol AmendmentJune 3rd 2021
A new treatment arm of a phase 2 trial examining PDS0101 plus pembrolizumab in patients with HPV-related head and neck cancers will be opened to patients with immune checkpoint inhibitor–pretreated disease.
High Tumor Mutation Burden Predicts Response to Immune Checkpoint Blockade for Some Cancer TypesApril 3rd 2021
Data investigating the predictive capabilities of high tumor mutation burden found it to be predictive of response to immune checkpoint blockade in some, but not all, types of cancers.
Leading Anticancer Immunotherapeutics to Be Assessed for Continued Use for Indications Granted Accelerate ApprovalMarch 12th 2021
Indications for pembrolizumab, nivolumab, and atezolizumab are set for examination under the FDA’s Oncologic Drugs Advisory Committee for indications granted accelerated approval in breast, urothelial, gastric, and liver cancers.
Tislelizumab Improves OS Compared With Chemo in Advanced Unresectable or Metastatic ESCCJanuary 28th 2021
The phase 3 RATIONALE 302 trial demonstrated that compared to chemotherapy, tislelizumab showed a statistically significant and clinically meaningful improvement in overall survival in the intention-to-treat population of patients with advanced or metastatic esophageal squamous cell carcinoma.
Strategies Proposed to Improve Management of Immune-Related Adverse EventsJanuary 11th 2021
Though the majority of immune-related adverse events (irAEs) can be managed with corticosteroids and other immunosuppressive treatments, life-threatening and sometimes fatal events have still been reported thus revealing a need to develop measures for effective management.
Ongoing Phase 1/2 Trial of FLX475 Shows Promising Activity in Multiple Cancer IndicationsNovember 17th 2020
The results demonstrated preliminary evidence of monotherapy activity, encouraging efficacy in combination with the PD-1 checkpoint inhibitor pembrolizumab (Keytruda), and biomarker data supporting FLX475’s mechanism of action.
Higher Serum PD-L1 Level Predicts Increased OS With Lapatinib vs Trastuzumab in CCTG MA.31 StudyOctober 18th 2020
The researchers hypothesized “that serum PD-L1 may identify a subgroup of patients with HER2-positive [metastatic breast cancer] who may benefit the most from the addition of novel immunotherapies to trastuzumab.”
6-Month PFS for 12-Month OS Model Appears Effective for Estimating 12-Month OSOctober 7th 2020
Researchers suggested these findings may assist in better selection and prioritization of immune checkpoint inhibitor agents for testing in randomized clinical trials based on phase 2 single arm randomized clinical trial results.
Adding Immunotherapy to Radiotherapy May Improve OS in Patients with Brain MetastasesOctober 3rd 2020
This study found that the addition of immunotherapy to radiotherapy was associated with improved overall survival compared with radiotherapy alone in patients with brain metastases who received definitive surgery of the primary tumor site.
FDA Clears Phase 1 Clinical Trial of ATA2271 for Treatment of Advanced MesotheliomaSeptember 15th 2020
The FDA accepted an investigational new drug application providing clearance to begin an open-label, single-arm phase 1 clinical trial of ATA2271, a next-generation mesothelin targeting CAR T-cell therapy.
ICIs May be Used as Individualized Therapy in Select Solid Organ Transplant RecipientsAugust 31st 2020
Though further research is necessary, researchers suggested that immune checkpoint inhibitors can be used as an individualized therapy in certain patients who have undergone solid organ transplantation.
Dermatologic Care May Be Linked to Increased Adherence to Prophylaxis Protocols for EGFRi-Associated RashAugust 29th 2020
A restrospective study published in JAMA Dermatology found that integrating dermatologic care into oncology practices might be associated with an increased adherence to evidence-based prophylaxis for EGFRi-associated rash.
Study Shows Nivolumab-Chemo Combination Improves Survival in Gastric and Esophageal CancersAugust 11th 2020
Bristol Myers Squibb announced that their phase 3 CheckMate-649 trial demonstrated superior overall survival and profession-free survival using nivolumab plus chemotherapy to treat patients with gastric and esophageal cancers.
Personalized Cancer Vaccine with Atezolizumab Shows Promise in Advanced Solid TumorsJune 22nd 2020
RO7198457 in combination with atezolizumab induced significant levels of neoantigen-specific immune responses with a manageable safety profile in patients with locally advanced or metastatic solid tumors.
Immune-Related Adverse Events Involving Multiple Organ Sites in a Patient Treated With Nivolumab Plus IpilimumabMay 13th 2020
Experts discuss the case of a 56-year-old white man who presents with multiple immune-related adverse events
Model Can Predict Patient Outcomes to Immunotherapy, Engineer Proper RegimensMay 11th 2020
A clinically applicable mathematical model was developed by researchers to predict outcomes to immunotherapy for patients with cancer previously treated with anti–CTLA-4 or anti–PD-1/PD-L1 antibodies.
Interim Data from KEYNOTE-555 Cohort B Demonstrate Benefit of Alternative Dosing RegimenApril 29th 2020
Interim data from cohort B of KEYNOTE-555, a phase I trial evaluating a 400 mg every 6-week dosing regimen of pembrolizumab in patients with metastatic melanoma, demonstrated a consistent benefit-risk profile.